AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Autonomix Medical to Present at Webull Financial Corporate Connect Webinar Series.
ByAinvest
Friday, Aug 15, 2025 9:21 am ET1min read
Autonomix Medical will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on Thursday, August 21st at 2:20 PM ET. Brad Hauser, President and CEO, will present. The webinar is part of a series hosted by Webull Financial, a leading online brokerage platform.
Title: Autonomix Medical to Present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAutonomix Medical, Inc. (NASDAQ: AMIX), a medical device company specializing in precision nerve-targeted treatments, will present at the Webull Financial Corporate Connect Webinar Series focused on Biotech/MedTech companies. The virtual presentation will be delivered by Brad Hauser, President and CEO, on Thursday, August 21, 2025, at 2:20 PM ET. The event is part of a broader virtual conference taking place from August 19-21, 2025.
The Webull Financial Corporate Connect Webinar Series: Biotech/MedTech is a platform designed to connect investors with innovative companies in the biotechnology and medical technology sectors. Webull Financial, a leading online brokerage platform, empowers self-directed investors with cutting-edge technology and low-cost trading options. The platform is committed to providing a seamless and rewarding experience for traders of all levels, with advanced charting tools and real-time market data [1].
Autonomix Medical is focused on advancing innovative technologies to revolutionize the diagnosis and treatment of diseases involving the nervous system. The company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. This technology could enable transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body [2].
Autonomix is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. The company's technology has the potential to address dozens of potential indications, including cardiology, hypertension, and chronic pain management, across a wide disease spectrum. However, it is important to note that the technology is still investigational and has not yet been cleared for marketing in the United States [3].
The presentation by Brad Hauser, President and CEO of Autonomix Medical, will provide insights into the company's innovative technology and its potential impact on the healthcare industry. Investors and financial professionals are encouraged to register for the webinar to gain a deeper understanding of Autonomix Medical's advancements and future prospects.
References:
[1] https://finance.yahoo.com/news/autonomix-medical-inc-present-webull-130000755.html
[2] https://www.globenewswire.com/news-release/2025/08/15/3134247/0/en/Autonomix-Medical-Inc-to-Present-at-the-Webull-Financial-Corporate-Connect-Webinar-Series-Biotech-MedTech.html
[3] https://www.stocktitan.net/news/AMIX/autonomix-medical-inc-to-present-at-the-webull-financial-corporate-x47007znev3x.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet